Home - Link
Pulmonary Hypertension - Scottish Pulmonary Vascular Unit - Health Care Professional Section

 

WHAT IS PH?

REFERRAL GUIDELINES

TREATMENT

CLINICAL TRIALS

DISCLAIMER

........................................

HOME : NEWS

REFERRAL GUIDELINES

 

The Scottish Pulmonary Vascular Unit was established in 1999 with funding from the National Services Division of Scotland. The unit aims to provide evaluation, investigation and initiation of treatment for all patients with severe pulmonary hypertension in Scotland.


Pulmonary hypertension is more common than previously recognised and new treatments have led to an improved prognosis. There are a variety of options for treatment including high dose calcium channel blockers, endothelin receptor antagonists (bosentan, ambrisentan), PDE-5 inhibitors (sildenafil, tadalafil) and prostaglandin analogues (nebulised Iloprost and intravenous Epoprostenol). New agents are in the process of being licensed, and clinical trials of other agents are ongoing.


Specialist supervision of all patients with pulmonary hypertension remains necessary: treatment is increasingly complex and expensive and requires careful ongoing scrutiny.

 

 

 

Border
SCOTTISH PULMONARY VASCULAR UNIT - All rights reserved - Clydebank, Scotland - 0141 951 5497 - SPVUnit@gjnh.scot.nhs.uk